FOR SUPPORT, CALL 1-866-APF-3635 (273-3635)
Scenesse was approved by the FDA on October 8 as a treatment to increase pain-free time in the light for patients with EPP.
The FDA has granted APPROVAL for Afamelanotide (Scenesse) for the treatment of Erythropoietic Protoporphyria!
Submissions are being accepted for travel stipends to attend the 2020 Rare Disease Week
The set date for the FDA decision regarding approval of Scenesse is 10 days away.
The ICPP meeting held in Milan, Italy, September 8-11, was a global success!
The American Porphyria Foundation hosted a CEP Patient Education and Support Meeting via online webinar.
We are excited to share that Recordati Rare Diseases Canada Inc. announced...
